DBV Technologies: Two Regulatory Submissions Planned in 2026 for Viaskin Peanut Patch
DBV Technologies unveils its regulatory submission schedule for its flagship pediatric allergy treatment. The French biotech plans two biologics license applications (BLA) this year, respectively for children aged 4 to 7 years and toddlers aged 1 to 3 years, as well as the launch of a new Phase 2 study in infants aged 6 to 12 months.
DBV Technologies sets a brisk pace for its flagship candidate, the VIASKIN Peanut patch. The company plans to file its first biologics license application in the first half of 2026 for children aged 4 to 7 years, followed by a second submission in the second half for the 1 to 3-year-old age group. This dual request covers an extension of the pediatric population allergic to peanuts, potentially broadening the accessible patient base. Daniel Tassé, CEO, emphasized an approach marked by 'extreme precision and determination' in product development.
A Groundbreaking Study Planned for Very Young Children
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Beyond regulatory filings, DBV announces the initiation of the THRIVE trial, a Phase 2 study aimed at infants aged 6 to 12 months. This trial will assess the efficacy and safety of the VIASKIN Peanut patch to enable peanut consumption after at least three years of treatment. The study was announced last year at the American College of Asthma, Allergy, and Immunology congress. Its launch represents an extension of the treatment strategy to younger patients, thus covering the entire spectrum of pediatric ages allergic to peanuts.
Execution Challenges and Regulatory Visibility
These three milestones (two BLAs and a new study) position DBV Technologies at a pivotal phase of its development in 2026. The concentration of these major events in a single year will be decisive for the future commercial trajectory of the group.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
